Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768734 | 1.00 | TMPRSS2 (0.39) | TMPRSS2TDP1NPC1ALDH1A1ATM | |
| SCHEMBL16708475 | 1.00 | TMPRSS2 (0.39) | TMPRSS2TDP1NPC1ALDH1A1ATM | |
| SCHEMBL19101754 | 0.93 | TMPRSS2 (0.40) | TMPRSS2TDP1NPC1ALDH1A1ATM | |
| SCHEMBL18371671 | 0.83 | POLRMT (0.39) | TMPRSS2TDP1 | |
| SCHEMBL16708500 | 0.83 | POLRMT (0.39) | TMPRSS2TDP1 | |
| SCHEMBL16708478 | 0.82 | TMPRSS2 (0.39) | TMPRSS2TDP1NPC1RAB9A | |
| SCHEMBL19101768 | 0.81 | TMPRSS2 (0.42) | TMPRSS2TDP1 | |
| SCHEMBL16708476 | 0.81 | SMN1; SMN2 (0.35) | TMPRSS2TDP1NPC1ALDH1A1RAB9A | |
| SCHEMBL16708479 | 0.80 | TDP1 (0.35) | TMPRSS2TDP1NPC1ALDH1A1ATM | |
| SCHEMBL16708474 | 0.80 | TMPRSS2 (0.34) | TMPRSS2TDP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701682-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170008897-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008897-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885TDP1 624/4885NPC1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.